Dysregulation of cellular epigenetic machinery is linked to the pathogenesis of a number of malignancies and has been studied extensively in myelodysplastic syndromes and acute myeloid leukemia. Alteration of DNA methylation in cancer cells results in transcriptional silencing of tumor suppressor genes. DNA methyltransferase inhibitors, such as azacitidine and decitabine, have been used to reexpress these genes and have demonstrated therapeutic benefits in both benign and malignant diseases. In this chapter, we discuss the clinical application of demethylating agents, the data that have led to their approval in hematologic diseases, and the future potential uses of these agents, both alone and in combination.
|Title of host publication||Medical Epigenetics|
|Number of pages||11|
|State||Published - 1 Jan 2021|
- Acute myeloid leukemia
- DNA methyltransferase inhibitors
- Hypomethylating agents
- Myelodysplastic syndromes